Boehringer Ingelheim and NascaCell announce research collaboration on aptamers
"We are delighted to work together with Boehringer's high-class research team", said Dr. Andreas Jenne, NascaCell's managing director. "Within our collaboration aptamers will be used to identify new druggable sites on protein targets. Our approach takes advantage of the unique properties of aptamers to specifically inactivate a particular functional epitope of a protein. Such aptamers may be subsequently used to discover novel small molecule lead compounds."
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.